Polymorphisms in Genes Coding for GRK2 and GRK5 and Response Differences in Antihypertensive-treated Patients

Overview

Journal Pharmacogenet Genomics

Specialties Genetics
Pharmacology

Date 2010 Dec 4

PMID 21127457

Citations 36

Authors

Maximilian T Lobmeyer

Liewei Wang

Issam Zineh

Stephen T Turner

John G Gums

Arlene B Chapman

Rhonda M Cooper-DeHoff

Amber L Beitelshees

Kent R Bailey

Eric Boerwinkle

Carl J Pepine

Julie A Johnson

Affiliations

Soon will be listed here.

Abstract

Objectives: The G-protein-coupled receptor kinases (GRKs) GRK2 and GRK5 are important regulators of β-adrenergic signaling. This study characterized single-nucleotide polymorphisms (SNPs) in the GRK2 gene (ADRBK1) and determined if these and a GRK5 Gln41Leu polymorphism affect the blood pressure (BP) response to atenolol or hydrochlorothiazide or adverse cardiovascular outcomes in hypertensives.

Methods: ADRBK1 regions were sequenced for 48 individuals. Putative functional SNPs were tested for mRNA expression differences in 96 lymphoblastoid cell line samples and 12 leukocyte samples from hypertensives. BP response to atenolol and hydrochlorothiazide by ADRBK1 SNPs and GRK5 Gln41Leu was tested in 418 patients from the Pharmacogenomic Evaluation of Antihypertensive Responses Study using linear regression. The influence of ADRBK1 SNPs and GRK5 Gln41Leu on death, myocardial infarction or stroke in treated hypertensives was evaluated in a case-control cohort (1 : 3) of the International Verapamil SR/Trandolapril Study GENEtic Substudy using logistic regression models.

Results: A novel ADRBK1 promoter SNP was not associated with differential GRK2 expression. GRK5 Leu41 decreased the risk for adverse cardiovascular outcomes independent of treatment strategy (adjusted odds ratio 0.535, 95% confidence interval: 0.313-0.951, P=0.0222), but was not associated with BP response to antihypertensive medication. An ADRBK1 SNP (rs1894111 G>A) showed a signal for association with systolic and diastolic BP response to hydrochlorothiazide in Whites [diastolic BP: -11.29±3.74 (G/A) versus -4.26±4.79 mmHg (G/G), P=0.0034 and systolic BP: -18.37±14.90 (G/A), -8.11±7.55 mmHg (G/G), P=0.0191].

Conclusion: The GRK5 Leu41 allele protects from adverse cardiovascular outcomes in treated hypertensives.

Citing Articles

Blood indices of inflammation and their association with hypertension in smokers: analysis using data mining approaches.

Ghoflchi S, Mansoori A, Islampanah M, Arab Yousefabadi S, Poudineh M, Derakhshan-Nezhad E J Hum Hypertens. 2024; 39(1):29-37.

PMID: 39472721 DOI: 10.1038/s41371-024-00975-6.

Effect of Clinical and Genetic Factors on the Development of Postoperative Atrial Fibrillation After Coronary Artery Bypass Grafting (CABG) in Egyptian Patients Receiving Beta-Blockers.

El Gindy D, Solayman M, Khorshid R, Schaalan M, El Wakeel L Cardiovasc Drugs Ther. 2022; 38(1):99-108.

PMID: 36107363 PMC: 10876817. DOI: 10.1007/s10557-022-07380-6.

Comprehensive insights in GRK4 and hypertension: From mechanisms to potential therapeutics.

Yang J, Hall J, Jose P, Chen K, Zeng C Pharmacol Ther. 2022; 239:108194.

PMID: 35487286 PMC: 9728143. DOI: 10.1016/j.pharmthera.2022.108194.

Pharmacogenetics to guide cardiovascular drug therapy.

Duarte J, Cavallari L Nat Rev Cardiol. 2021; 18(9):649-665.

PMID: 33953382 PMC: 8364496. DOI: 10.1038/s41569-021-00549-w.

The Roles of GRKs in Hemostasis and Thrombosis.

Chen X, Zhao X, Cooper M, Ma P Int J Mol Sci. 2020; 21(15).

PMID: 32731360 PMC: 7432802. DOI: 10.3390/ijms21155345.

References

Moyer A, Salavaggione O, Wu T, Moon I, Eckloff B, Hildebrandt M . Glutathione s-transferase p1: gene sequence variation and functional genomic studies. Cancer Res. 2008; 68(12):4791-801. PMC: 2490824. DOI: 10.1158/0008-5472.CAN-07-6724. View

Kurnik D, Cunningham A, Sofowora G, Kohli U, Li C, Friedman E . GRK5 Gln41Leu polymorphism is not associated with sensitivity to beta(1)-adrenergic blockade in humans. Pharmacogenomics. 2009; 10(10):1581-7. PMC: 2820245. DOI: 10.2217/pgs.09.92. View

Johnson J, Boerwinkle E, Zineh I, Chapman A, Bailey K, Cooper-DeHoff R . Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study. Am Heart J. 2009; 157(3):442-9. PMC: 2671287. DOI: 10.1016/j.ahj.2008.11.018. View

Gabriel S, Schaffner S, Nguyen H, Moore J, Roy J, Blumenstiel B . The structure of haplotype blocks in the human genome. Science. 2002; 296(5576):2225-9. DOI: 10.1126/science.1069424. View

Goldstein R, Boccuzzi S, Cruess D, Nattel S . Diltiazem increases late-onset congestive heart failure in postinfarction patients with early reduction in ejection fraction. The Adverse Experience Committee; and the Multicenter Diltiazem Postinfarction Research Group. Circulation. 1991; 83(1):52-60. DOI: 10.1161/01.cir.83.1.52. View

Barjon J, Rouleau J, Bichet D, Juneau C, de Champlain J . Chronic renal and neurohumoral effects of the calcium entry blocker nisoldipine in patients with congestive heart failure. J Am Coll Cardiol. 1987; 9(3):622-30. DOI: 10.1016/s0735-1097(87)80057-8. View

Cresci S, Kelly R, Cappola T, Diwan A, Dries D, Kardia S . Clinical and genetic modifiers of long-term survival in heart failure. J Am Coll Cardiol. 2009; 54(5):432-44. PMC: 2749467. DOI: 10.1016/j.jacc.2009.05.009. View

Barrett J, Fry B, Maller J, Daly M . Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2004; 21(2):263-5. DOI: 10.1093/bioinformatics/bth457. View

Yuan H, Chiou J, Tseng W, Liu C, Liu C, Lin Y . FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization. Nucleic Acids Res. 2006; 34(Web Server issue):W635-41. PMC: 1538865. DOI: 10.1093/nar/gkl236. View

10.

Penela P, Murga C, Ribas C, Tutor A, Peregrin S, Mayor Jr F . Mechanisms of regulation of G protein-coupled receptor kinases (GRKs) and cardiovascular disease. Cardiovasc Res. 2005; 69(1):46-56. DOI: 10.1016/j.cardiores.2005.09.011. View

11.

Pepine C, Handberg E, Cooper-DeHoff R, Marks R, Kowey P, Messerli F . A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): a randomized controlled trial. JAMA. 2003; 290(21):2805-16. DOI: 10.1001/jama.290.21.2805. View

12.

Ronaghi M, Uhlen M, Nyren P . A sequencing method based on real-time pyrophosphate. Science. 1998; 281(5375):363, 365. DOI: 10.1126/science.281.5375.363. View

13.

Packer M, OConnor C, Ghali J, Pressler M, Carson P, Belkin R . Effect of amlodipine on morbidity and mortality in severe chronic heart failure. Prospective Randomized Amlodipine Survival Evaluation Study Group. N Engl J Med. 1996; 335(15):1107-14. DOI: 10.1056/NEJM199610103351504. View

14.

Sandelin A, Alkema W, Engstrom P, Wasserman W, Lenhard B . JASPAR: an open-access database for eukaryotic transcription factor binding profiles. Nucleic Acids Res. 2003; 32(Database issue):D91-4. PMC: 308747. DOI: 10.1093/nar/gkh012. View

15.

Beitelshees A, Gong Y, Wang D, Schork N, Cooper-DeHoff R, Langaee T . KCNMB1 genotype influences response to verapamil SR and adverse outcomes in the INternational VErapamil SR/Trandolapril STudy (INVEST). Pharmacogenet Genomics. 2007; 17(9):719-29. PMC: 2713584. DOI: 10.1097/FPC.0b013e32810f2e3c. View

16.

Liggett S, Cresci S, Kelly R, Syed F, Matkovich S, Hahn H . A GRK5 polymorphism that inhibits beta-adrenergic receptor signaling is protective in heart failure. Nat Med. 2008; 14(5):510-7. PMC: 2596476. DOI: 10.1038/nm1750. View

17.

. The effect of diltiazem on mortality and reinfarction after myocardial infarction. N Engl J Med. 1988; 319(7):385-92. DOI: 10.1056/NEJM198808183190701. View

18.

Materson B, Reda D, Cushman W, Massie B, FREIS E, Kochar M . Single-drug therapy for hypertension in men. A comparison of six antihypertensive agents with placebo. The Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. N Engl J Med. 1993; 328(13):914-21. DOI: 10.1056/NEJM199304013281303. View

19.

Dahlof B, Sever P, Poulter N, Wedel H, Beevers D, Caulfield M . Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm.... Lancet. 2005; 366(9489):895-906. DOI: 10.1016/S0140-6736(05)67185-1. View

20.

Johnson J, Gong Y, Bailey K, Cooper-DeHoff R, Chapman A, Turner S . Hydrochlorothiazide and atenolol combination antihypertensive therapy: effects of drug initiation order. Clin Pharmacol Ther. 2009; 86(5):533-9. PMC: 2765524. DOI: 10.1038/clpt.2009.101. View